PL428089A1 - Peptides for use in prevention and treatment of inflammation - Google Patents

Peptides for use in prevention and treatment of inflammation

Info

Publication number
PL428089A1
PL428089A1 PL428089A PL42808918A PL428089A1 PL 428089 A1 PL428089 A1 PL 428089A1 PL 428089 A PL428089 A PL 428089A PL 42808918 A PL42808918 A PL 42808918A PL 428089 A1 PL428089 A1 PL 428089A1
Authority
PL
Poland
Prior art keywords
prevention
treatment
lys
inflammation
leu
Prior art date
Application number
PL428089A
Other languages
Polish (pl)
Other versions
PL239303B1 (en
Inventor
Paulina KOSIKOWSKA-ADAMUS
Adam LESNER
Joanna Kozieł
Anna GOLDA
Original Assignee
Uniwersytet Gdański
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Gdański, Uniwersytet Jagielloński filed Critical Uniwersytet Gdański
Priority to PL428089A priority Critical patent/PL239303B1/en
Priority to PCT/PL2019/050072 priority patent/WO2020117081A1/en
Publication of PL428089A1 publication Critical patent/PL428089A1/en
Publication of PL239303B1 publication Critical patent/PL239303B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem zgłoszenia jest peptyd o poniższym wzorze, do zastosowania w prewencji i leczeniu stanu zapalnego, w tym w prewencji i leczeniu sepsy Tyr-a/a-Gly-Phe-Leu-Arg-O2Oc-lle-Lys-Lys-lle-Leu-Ser-lys-lle-Lys-Lys-Leu-Leu-NH2.The subject of the application is a peptide with the following formula for use in the prevention and treatment of inflammation, including the prevention and treatment of sepsis Tyr-a / a-Gly-Phe-Leu-Arg-O2Oc-lle-Lys-Lys-lle-Leu- Ser-lys-lle-Lys-Lys-Leu-Leu-NH2.

PL428089A 2018-12-06 2018-12-06 Peptides for use in prevention and treatment of inflammation PL239303B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL428089A PL239303B1 (en) 2018-12-06 2018-12-06 Peptides for use in prevention and treatment of inflammation
PCT/PL2019/050072 WO2020117081A1 (en) 2018-12-06 2019-12-04 Peptides for use in prevention and treatment of inflammation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL428089A PL239303B1 (en) 2018-12-06 2018-12-06 Peptides for use in prevention and treatment of inflammation

Publications (2)

Publication Number Publication Date
PL428089A1 true PL428089A1 (en) 2020-06-15
PL239303B1 PL239303B1 (en) 2021-11-22

Family

ID=69375982

Family Applications (1)

Application Number Title Priority Date Filing Date
PL428089A PL239303B1 (en) 2018-12-06 2018-12-06 Peptides for use in prevention and treatment of inflammation

Country Status (2)

Country Link
PL (1) PL239303B1 (en)
WO (1) WO2020117081A1 (en)

Also Published As

Publication number Publication date
PL239303B1 (en) 2021-11-22
WO2020117081A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
CO2019007298A2 (en) Inhibitors of context-permissive isoform-specific tgfβ1 and their use
ECSP22012826A (en) PARP1 INHIBITORS
MX2023013096A (en) PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND.
MY209489A (en) Antibody against human il-4ra and use thereof
GEAP202215479A (en) Magl inhibitors
CL2021003105A1 (en) Masp-2 inhibitors and methods of use (divisional application no. 202003083)
MX2020002823A (en) FLUOROPHENIL BETA-HYDROXYETHYLAMINES AND ITS USE IN THE TREATMENT OF HYPERGLYCEMIA.
EA202091964A1 (en) COMBINED PRODUCT BASED ON Bcl-2 INHIBITOR AND MDM2 INHIBITOR AND ITS APPLICATION IN THE PREVENTION AND / OR TREATMENT OF DISEASES
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
EA202192101A1 (en) COMPOUNDS AND THEIR APPLICATIONS
BR112019003816A2 (en) hair rinse treatment composition, method for treating chemically damaged hair and use of a composition
CL2021002318A1 (en) Methods of treating amyloidosis by
SV2018005702A (en) 1,3,4-TIADIAZOL COMPOUNDS AND THEIR USE IN CANCER TREATMENT
PH12021550122A1 (en) Solubilized apyrases, methods and use
CL2021001922A1 (en) Procedures for treatment of diseases with magl inhibitors.
CO6592047A2 (en) Topical ophthalmic peptide formulation
MX2021008005A (en) Peptide libraries and methods of use thereof.
EA202090424A1 (en) BICYCLIC HISTONDEACETYLASE INHIBITORS
EP3789396C0 (en) SYNTHETIC PEPTIDE SP2 AND USE THEREOF
PL4071171T3 (en) ANTI-TM4SF4 ANTIBODY AND ITS USE
MX2021005766A (en) METHODS OF MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH INFLAMMATION.
PL428089A1 (en) Peptides for use in prevention and treatment of inflammation
IL280101A (en) Peptide compounds and their therapeutic uses
WO2020212514A8 (en) Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer
EA202192532A1 (en) MIRIKIZUMAB FOR USE IN THE TREATMENT OF CROHN'S DISEASE